WARNINGS AND PRECAUTIONS SECTION
Rx Only
For topical use only
Federal Law restricts this device to sale by or on order of a licensed healthcare practitioner.
Rx Only
For topical use only
Federal Law restricts this device to sale by or on order of a licensed healthcare practitioner.
[EN] Description
StrataCTX is an occlusive, non-resorbable, self-drying and transparent gel.
When used as directed StrataCTX dries to form a protective layer that is gas permeable and waterproof which hydrates and protects compromised skin areas and superficial wounds from chemical and microbial invation.
StrataCTX helps to promote a moist healing environment.
This moist wound healing environment promotes faster re-epithelialization* and reduces the skin's acute inflammatory response.
StrataCTX is suitable for large surface areas and contoured skin like head, face, hand and foot as well as joints and hairy areas without the need for shaving.
Indication for use
StrataCTX is intended to be used under the direction of healthcare practitioners in the management of cutaneous reactions.
StrataCTX is indicated for use on all types of wounds, toxic and compromised skin including:
StrataCTX is indicated for the relief of dry, itching, flaking, peeling and irritated skin, as well as the symptomatic relief of pain, redness and heat sensation.
StrataCTX may be directly applied to dry skin, open wounds and compromised or desquamating skin surfaces, including cutaneous rashes.
StrataCTX gel is bacteriostatic and inert.
It contains no alcohols, parabens or fragrances.
StrataCTX can be used with or without a secondary protective dressing.
StrataCTX is suitable for children and people with sensitive skin.
StrataCTX is intented for single patient use.
Directions for use
On the first use of 1.75 oz (50g) tubes remove the cap, then the protective seal and close with the cap after use.
Ensure that the affected superficial area is clean and dry.
Apply a very thin layer of StrataCTX directly to the affected area and allow the gel to dry.
When applied correctly to exposed areas, StrataCTX should be dry in 5-6 minutes.
If it takes longer to dry you have probably applied too much.
Gently remove the excess with a clean tissue or gauze and allow the drying process to continue.
Once dry, StrataCTX may be covered by sunscreen, cosmetics and clothing.
StrataCTX should be applied at least twice daily to affected areas, as needed or as advised by your physician.
For best results StrataCTX should be maintained in continuous contact with the skin (24 hours a day/7 days a week).
How much StrataCTX do I need?
StrataCTX gel is an advanced formulation that requires substantially less product per application than typical creams or gels.
StrataCTX 1.75 oz (50g) is enough to treat an area of 6x12 inch (15x30 cm) twice per day for 30 days.
Warning:
Contraindications:
Do not administer to patients with known hypersensitivity to the ingredients of this product.
STERILE UNTIL OPENED
Ingredients: Dimethylpolysiloxane, dihydroxysiloxane and alkylmethylsiloxane.
How supplied:
StrataCTX 1.75 oz (50g) tube
Product identification code:
73661-421-50
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 73661-421-50 | StrataCTX | 1 in 1 BOX | 1 | 1 | ||
| 73661-421-50 | StrataCTX | 50 g in 1 TUBE | 50 | 1 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 73661-421-50 | GM - Gram | 73661-421 | 04a65ce5-e2aa-4b0e-80c1-140b65265366 | 1 | 2020-07-13 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 73661-421 | 73661-421-50 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| DIMETHICONE | 92RU3N3Y1O | IACT |
| DIMETHICONOL (2000 CST) | T74O12AN6Y | IACT |
| DIDECYLDIMONIUM CHLORIDE | JXN40O9Y9B | IACT |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Adverse event summaries are temporarily unavailable. Other product information remains available.